Luxembourg Centre for Systems Biomedicine Appoints BIOBASE Genome Trax™ to Identify Human Genome Variations
News Jul 18, 2012
In addition, both groups will collaborate to establish a hub of expertise for the application of BIOBASE products and will provide data analysis, training, and support to researchers in Luxembourg and surrounding countries.
Genome Trax™ prioritizes human genome variants in whole genome or exome data that merit further investigation. The tool maps NGS data to known features such as disease mutations and regulatory sites. In addition, Genome Trax™ identifies novel mutations that are likely to affect the function of candidate disease genes, and enables users to filter out the millions of irrelevant variants.
Reinhard Schneider, Head of the Bioinformatics core facility at the LCSB, stated: “The mutation, regulation and pharmacogenomics data in Genome Trax™ are crucial for the annotation of our clinical data. These annotations are unparalleled in their comprehensiveness and quality, and I see this collaboration as a strategic partnership to advance the clinical application of NGS technology”.
"The LCSB is turning into one of the leading centers for bioinformatics worldwide and the bioinformatics facility, led by Dr. Reinhard Schneider, needs to interpret large volumes of data from the life sciences. This undertaking is powered by massive hardware, and needs the best available software and databases. LCSB chose BIOBASE as a strategic partner and I am looking forward to this collaboration.” said Frank Schacherer, CTO of BIOBASE.
Researchers have shown that a single systemic treatment using CRISPR genome editing technology can safely and stably correct a genetic disease -- Duchenne muscular dystrophy (DMD) -- for more than a year in mice, despite observed immune responses and alternative gene editing outcomes.READ MORE